Market Size of France Contraceptive Devices Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 458.16 Million |
| Market Size (2029) | USD 624.78 Million |
| CAGR (2024 - 2029) | 6.40 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
France Contraceptive Devices Market Analysis
The France Contraceptive Devices Market size is estimated at USD 458.16 million in 2024, and is expected to reach USD 624.78 million by 2029, growing at a CAGR of 6.40% during the forecast period (2024-2029).
The pandemic adversely impacted the contraceptive devices market in France. For instance, as per the study published in April 2022, by the National Library of Medicine, the dispensing of contraceptives in France was remarkably low during the COVID-19 pandemic. Prescriptions for long-acting contraceptive use and women under 25 years were the most substantially impacted. Dispensing of emergency contraceptives (EC) and intrauterine contraceptives decreased more substantially during the first lockdown and then increased moderately at the end of 2020 and in 2021. Hence, with the resumption of services due to the decrease in COVID-19 cases, the market started to recover and is expected to maintain its growth over the forecast period.
The increasing awareness about sexually transmitted diseases (STDs), the rising rate of unintended pregnancies, and the rise in government initiatives are the major factors driving the market. For instance, in November 2021, a report published by the WHO stated that sexual intercourse is the second most commonly reported mode of transmission of STDs in the European Union, accounting for 29.7% of all HIV diagnoses. The highest proportions were observed in France (53.0%) in 2021. Thus, the high burden of STDs in France than other European countries is expected to increase the demand for contraceptive devices, which is expected to boost the market's growth over the forecast period.
Similarly, the report published in October 2021 by the HPV World stated that the prevalence of HPV 16 and 18 among adult women with normal cytology is 4.7%, with low-grade cervical lesions is 26.3%, with high-grade cervical lesions is 60.6%, and with cervical cancer is 75.6%. Such instances indicate that the demand for contraceptive devices may increase. Thereby, considerable market growth is anticipated over the forecast period.
However, side effects associated with the use of contraceptive devices may likely restrain the market over the forecast period.
